Kadimastem Company Top Insiders
| KMSTF Stock | USD 2.50 0.13 4.94% |
Kadimastem employs about 5 people. The company is managed by 5 executives with a total tenure of roughly 12 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Examination of Kadimastem's management performance can provide insight into the company performance.
| Arik Hasson Insider Exec Devel |
| Michal Izrael Insider VP Diseases |
Kadimastem |
Kadimastem Management Team Effectiveness
The company has return on total asset (ROA) of (0.7485) % which means that it has lost $0.7485 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (7.3543) %, meaning that it generated substantial loss on money invested by shareholders. Kadimastem's management efficiency ratios could be used to measure how well Kadimastem manages its routine affairs as well as how well it operates its assets and liabilities.Kadimastem Workforce Comparison
Kadimastem is rated fifth overall in number of employees category among its peers. The total workforce of Biotechnology industry is now estimated at about 433. Kadimastem claims roughly 5.0 in number of employees contributing just under 2% to stocks in Biotechnology industry.
Kadimastem Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Kadimastem Price Series Summation is a cross summation of Kadimastem price series and its benchmark/peer.
Kadimastem Notable Stakeholders
A Kadimastem stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kadimastem often face trade-offs trying to please all of them. Kadimastem's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kadimastem's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Arik Hasson | Exec Devel | Profile | |
| Michal Izrael | VP Diseases | Profile | |
| Yossi BenYossef | Honorary Consultant | Profile | |
| Asaf Shiloni | Chief Officer | Profile | |
| Pr MD | Chief CoFounder | Profile |
About Kadimastem Management Performance
The success or failure of an entity such as Kadimastem often depends on how effective the management is. Kadimastem management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kadimastem management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kadimastem management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. The company was founded in 2008 and is based in Ness Ziona, Israel. Kadimastem operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Kadimastem Workforce Analysis
Traditionally, organizations such as Kadimastem use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kadimastem within its industry.Kadimastem Manpower Efficiency
Return on Kadimastem Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 5.3M | |
| Net Loss Per Executive | 5.3M |
Complementary Tools for Kadimastem Pink Sheet analysis
When running Kadimastem's price analysis, check to measure Kadimastem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kadimastem is operating at the current time. Most of Kadimastem's value examination focuses on studying past and present price action to predict the probability of Kadimastem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kadimastem's price. Additionally, you may evaluate how the addition of Kadimastem to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |